Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) progresses from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Although metabolic stress is recognized as a central driver of MASLD initiation, the mechanisms by which early metabolic injury is converted into persistent inflammatory, fibrotic and oncogenic transcriptional programs remain incompletely defined. In particular, a conceptual framework linking altered metabolic cues to chromatin-associated molecular signatures is still lacking. Jumonji C domain-containing histone lysine demethylases (JmjC-KDMs) are Fe(II)/α-ketoglutarate-dependent dioxygenase enzymes, placing them at a critical interface between metabolic perturbation and epigenetic remodeling. In this review, we summarize current evidence for the functional roles of JmjC-KDMs across the MASLD continuum, with particular emphasis on mechanistic links between JmjC-KDM dysregulation and metabolic dysfunction, inflammation, immune remodeling, fibrosis and hepatocarcinogenesis. We propose that JmjC-KDMs function as context-dependent epigenetic rheostats, with their effects shaped by metabolic cofactors, cell type, disease stage, substrate specificity and catalytic/non-catalytic functions. Finally, we discuss how this framework may inspire biomarker-guided, disease-stage- and cell-type-specific epigenetic strategies for MASLD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: